Archive for the ‘Hospital Clínic de Barcelona’ Category

Thursday February 02nd, 2017

Hospital Clinic-IDIBAPS coordinates a European project to obtain a functional cure for HIV with immunotherapy

The IDIBAPS and the Hospital Clínic of Barcelona lead a European project aimed at changing the current paradigm of HIV treatment by obtaining a functional cure. The main goal is to control HIV replication over long periods of time or throughout life without antiretroviral treatment. Dr. Felipe Garcia, senior consultant of the Infectious Diseases Department at Hospital Clínic and researcher of the IDIBAPS team on Infectious Diseases and AIDS, coordinates this study called HIVACAR. This initiative is part of the European research and innovation framework program Horizon 2020, has a total budget of 6.7 million euro and 14 institutions will participate, among clinical and research centers and European companies. In Spain, the other participating institutions are the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology (CNB-CSIC) and the Faculty of Economics and Business Sciences of the Complutense University of Madrid (UCM). Read the rest of this entry »

Comments Closed
Friday January 27th, 2017

IDIBAPS researchers review recent advances in rapid and effective treatment of depression

Drs. Francesc Artigas and Analía Bortolozzi, researchers of the team of Neuropharmacology and Experimental Neuropathology in the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the IIBB-CSIC, have just published a “Hot Topic” article in the first issue of 2017 in the journal Neuropsychopharmacology, one of the most prestigious in the field of Psychiatry and Neuropharmacology. This section of the journal, published at the beginning of each year, collects significant advances recently produced in the field.

The article briefly reviews the advances made by the group in the development of new experimental strategies for a more rapid and effective treatment of depression through the use of interfering RNA molecules conjugated to serotonin reuptake inhibitors. These advances were published in the journals Molecular Psychiatry and Traslational Psychiatry and show that these conjugates produce an antidepressant effect faster than the conventional drugs in experimental models, which means a remarkable advance with a possible therapeutic application.

Article reference:

Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder
Artigas F, Bortolozzi A.
Neuropsychopharmacology. 2017 Jan;42(1):371. doi: 10.1038/npp.2016.182.

Comments Closed
Thursday January 26th, 2017

Scientists at Salk Institute have made breakthroughs in the integration of human cells into embryos of a different species

Human iPS cells (green) contributed to a developing heart of 4-week-old pig embryo (Image: Salk Institute)Scientists at Salk Institute for Biological Studies in California have made breakthroughs on multiple fronts in the race to integrate pluripotent stem cells from one species into the early-stage development of another. This will allow to study the embryonic development of an organism, diseases, test new therapeutic drugs and the possibly grow transplantable. Dr. Juan Carlos Izpisúa, professor in Salk’s Gene Expression Laboratory, leads this study published in today’s issue of the journal Cell. Dr. Josep M. Campistol, CEO and nephrologist in Hospital Clínic and researcher in IDIBAPS, and scientists from the Catholic University of Murcia (UCAM), the Pedro Guillén Foundation, the CEMTRO Clinic in Madrid and the University of Murcia, have also participated.

Read the rest of this entry »

Comments Closed
Wednesday January 25th, 2017

Josep Dalmau, Chair of the new Autoimmune Neurology Section in the American Academy of Neurology

Dr. Josep Dalmau

Dr. Josep Dalmau, ICREA Professor of IDIBAPS, where he leads the Group Pathogenesis of autoimmune neuronal disorders, and consultant of the Neurology Department of Hospital Clínic, has been named Chair of the Autoimmune Neurology Section in the American Academy of Neurology (AAN). It is a newly created section that wants to differentiate itself from the classic concept of neuroimmunology, more linked to other types of diseases such as Multiple Sclerosis. The founders of the section are Drs. Sean Pittock, of the Mayo Clinic, and Jeffrey Gelfand, of the University of California San Francisco (UCSF). Read the rest of this entry »

Comments Closed

A treatment increases survival by 50% in mice with Niemann-Pick type C, a rare disease that affects brain and liver

Researchers from the IIBB-CSIC and the IDIBAPS publish an article in the journal Redox Biology in which they propose an alternative treatment for Niemann-Pick disease type C, a rare lysosomal pathology that causes neurodegeneration and impaired liver function. With a compound that crosses the blood-brain barrier, it is possible to increase the survival of the mice by 50% and to improve the neurological and motor problems related to the disease. Dr. José C. Fernández-Checa, head of the IDIBAPS team on Mitochondrial regulation of cell death and steatohepatitis, and Dr. Carmen García-Ruiz, from the same team, are the coordinators of the study, which has been carried out in collaboration with researchers from France and Chile. The first author of the study is Sandra Torres, predoctoral researcher in Dr. Fernández-Checa’s lab.

Read the rest of this entry »

Comments Closed
Wednesday January 18th, 2017

A diagnostic test for lung cancer detects genetic alterations which may remain hidden when conventional techniques are used

A study led by researchers from Hospital Clínic-IDIBAPS, in collaboration with Dexeus University Hospital, shows the effectiveness of a new genetic test for molecular diagnosis in lung cancer. This is the first time that a test for this type of tumor is implemented in clinical practice. It consists of analyzing three genes with an innovative genomic technology that allows detecting multiple alterations which may not be identified when conventional diagnostic techniques are used. If these genetic alterations are detected, the patient can be treated with an oral drug that has minimal toxicity and a very high clinical benefit. The study has been coordinated by Dr. Noemí Reguart, an oncologist at the Hospital Clínic-IDIBAPS, and Dr. Aleix Prat, head of the Clinical Oncology Department and of the IDIBAPS research team on Translational Genomics and directed therapies in solid tumors.

Read the rest of this entry »

Comments Closed
Page 4 of 58« First...23456...Last »